Free Trial
NASDAQ:LUNG

Pulmonx (LUNG) Stock Price, News & Analysis

Pulmonx logo
$1.56 -0.05 (-2.80%)
As of 03:09 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Pulmonx Stock (NASDAQ:LUNG)

Advanced

Key Stats

Today's Range
$1.57
$1.65
50-Day Range
$1.51
$1.86
52-Week Range
$1.47
$9.37
Volume
176,501 shs
Average Volume
436,790 shs
Market Capitalization
$63.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.66
Consensus Rating
Hold

Company Overview

Pulmonx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

LUNG MarketRank™: 

Pulmonx scored higher than 78% of companies evaluated by MarketBeat, and ranked 294th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pulmonx has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 5 buy ratings, 4 hold ratings, and 1 sell rating.

  • Upside Potential

    Pulmonx has a consensus price target of $7.66, representing about 386.6% upside from its current price of $1.58.

  • Amount of Analyst Coverage

    Pulmonx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Pulmonx's stock forecast and price target.
  • Earnings Growth

    Earnings for Pulmonx are expected to grow in the coming year, from ($1.55) to ($1.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pulmonx is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pulmonx is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pulmonx has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pulmonx's valuation and earnings.
  • Percentage of Shares Shorted

    3.53% of the outstanding shares of Pulmonx have been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmonx has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmonx has recently decreased by 19.10%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pulmonx does not currently pay a dividend.

  • Dividend Growth

    Pulmonx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.53% of the outstanding shares of Pulmonx have been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmonx has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmonx has recently decreased by 19.10%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Pulmonx has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Pulmonx this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for LUNG on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $54,234.00 in company stock.

  • Percentage Held by Insiders

    Only 6.80% of the stock of Pulmonx is held by insiders.

  • Percentage Held by Institutions

    91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pulmonx's insider trading history.
Receive LUNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LUNG Stock News Headlines

Another gold high? Here’s the move Wall Street is missing …
Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says the real opportunity is in a little-known strategy that has historically outpaced gold’s rallies many times over — including one past run where investors saw gains of more than 26,000%.tc pixel
Pulmonx (NASDAQ:LUNG) Cut to Sell at Wall Street Zen
Pulmonx files $200M mixed securities shelf
Pulmonx to Participate in September Investor Conferences
See More Headlines

LUNG Stock Analysis - Frequently Asked Questions

Pulmonx's stock was trading at $6.79 at the start of the year. Since then, LUNG shares have decreased by 76.8% and is now trading at $1.5750.

Pulmonx Corporation (NASDAQ:LUNG) announced its earnings results on Wednesday, July, 30th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. The company earned $23.86 million during the quarter, compared to analysts' expectations of $23.46 million. Pulmonx had a negative trailing twelve-month return on equity of 69.76% and a negative net margin of 62.88%.
Read the conference call transcript
.

Pulmonx (LUNG) raised $100 million in an IPO on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmonx investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD).

Company Calendar

Last Earnings
7/30/2025
Today
10/16/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:LUNG
CIK
1127537
Fax
N/A
Employees
250
Year Founded
1998

Price Target and Rating

High Price Target
$16.00
Low Price Target
$2.50
Potential Upside/Downside
+376.0%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$56.39 million
Net Margins
-62.88%
Pretax Margin
-62.28%
Return on Equity
-69.76%
Return on Assets
-36.26%

Debt

Debt-to-Equity Ratio
0.54
Current Ratio
5.35
Quick Ratio
4.63

Sales & Book Value

Annual Sales
$83.79 million
Price / Sales
0.78
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.17 per share
Price / Book
0.74

Miscellaneous

Outstanding Shares
40,750,000
Free Float
37,976,000
Market Cap
$65.61 million
Optionable
Optionable
Beta
0.42

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:LUNG) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners